Total Debt Summary of Novo Nordisk A/S

Novo Nordisk A/S's latest annual total debt in 2023 was 27 Billion DKK , up 4.74% from previous year.
Novo Nordisk A/S's latest quarterly total debt in 2024 Q2 was 57.06 Billion DKK , up 111.9% from previous quarter.
Novo Nordisk A/S reported annual total debt of 25.78 Billion DKK in 2022, down -3.23% from previous year.
Novo Nordisk A/S reported annual total debt of 26.64 Billion DKK in 2021, up 157.29% from previous year.
Novo Nordisk A/S reported quarterly total debt of 57.06 Billion DKK for 2024 Q2, up 111.9% from previous quarter.
Novo Nordisk A/S reported quarterly total debt of 27 Billion DKK for 2023 Q4, up 1.77% from previous quarter.

Annual Total Debt Chart of Novo Nordisk A/S (2023 - 1989)

Historical Annual Total Debt of Novo Nordisk A/S (2023 - 1989)

Year	Total Debt	Total Debt Growth
2023	27 Billion DKK	4.74%
2022	25.78 Billion DKK	-3.23%
2021	26.64 Billion DKK	157.29%
2020	10.35 Billion DKK	131.01%
2019	4.48 Billion DKK	770.49%
2018	515 Million DKK	-69.6%
2017	1.69 Billion DKK	639.74%
2016	229 Million DKK	-78.66%
2015	1.07 Billion DKK	49.03%
2014	720 Million DKK	234.88%
2013	215 Million DKK	-57.0%
2012	500 Million DKK	-41.38%
2011	853 Million DKK	-61.65%
2010	2.22 Billion DKK	60.23%
2009	1.38 Billion DKK	-40.21%
2008	2.32 Billion DKK	70.02%
2007	1.36 Billion DKK	-9.83%
2006	1.51 Billion DKK	-43.74%
2005	2.69 Billion DKK	57.72%
2004	1.7 Billion DKK	-1.48%
2003	1.73 Billion DKK	24.88%
2002	1.38 Billion DKK	-17.79%
2001	1.68 Billion DKK	-4.37%
2000	1.76 Billion DKK	-63.83%
1999	4.87 Billion DKK	76.93%
1998	2.75 Billion DKK	-11.13%
1997	3.1 Billion DKK	191.67%
1996	1.06 Billion DKK	-48.02%
1995	2.04 Billion DKK	-55.14%
1994	4.56 Billion DKK	6.01%
1993	4.3 Billion DKK	20.11%
1992	3.58 Billion DKK	16.69%
1991	3.07 Billion DKK	7.36%
1990	2.86 Billion DKK	-15.22%
1989	3.37 Billion DKK	60.55%

Year	Total Debt	Total Debt Growth
2024 Q1	26.92 Billion DKK	-0.29%
2024 Q2	57.06 Billion DKK	111.9%
2023 Q4	27 Billion DKK	1.77%
2023 Q3	26.53 Billion DKK	3.24%
2023 Q2	25.7 Billion DKK	0.73%
2023 FY	27 Billion DKK	4.74%
2023 Q1	25.51 Billion DKK	-1.03%
2022 Q4	25.78 Billion DKK	-0.71%
2022 Q3	25.96 Billion DKK	2.1%
2022 Q2	25.43 Billion DKK	-0.18%
2022 FY	25.78 Billion DKK	-3.23%
2022 Q1	25.48 Billion DKK	-4.37%
2021 FY	26.64 Billion DKK	157.29%
2021 Q1	9.65 Billion DKK	-6.77%
2021 Q2	13.76 Billion DKK	42.56%
2021 Q3	13.74 Billion DKK	-0.12%
2021 Q4	26.64 Billion DKK	93.81%
2020 Q1	4.11 Billion DKK	-8.32%
2020 FY	10.35 Billion DKK	131.01%
2020 Q3	4.1 Billion DKK	-0.94%
2020 Q2	4.14 Billion DKK	0.8%
2020 Q4	10.35 Billion DKK	152.34%
2019 Q3	4.34 Billion DKK	2.62%
2019 Q4	4.48 Billion DKK	3.22%
2019 FY	4.48 Billion DKK	770.49%
2019 Q1	4.31 Billion DKK	738.45%
2019 Q2	4.23 Billion DKK	-1.99%
2018 Q2	247 Million DKK	8.33%
2018 FY	515 Million DKK	-69.6%
2018 Q3	337 Million DKK	36.44%
2018 Q1	228 Million DKK	-86.54%
2018 Q4	515 Million DKK	52.82%
2017 Q1	613 Million DKK	167.69%
2017 Q3	260 Million DKK	-84.55%
2017 FY	1.69 Billion DKK	639.74%
2017 Q4	1.69 Billion DKK	551.54%
2017 Q2	1.68 Billion DKK	174.55%
2016 Q2	406 Million DKK	0.0%
2016 Q4	229 Million DKK	-49.78%
2016 Q1	406 Million DKK	-62.16%
2016 Q3	456 Million DKK	12.32%
2016 FY	229 Million DKK	-78.66%
2015 FY	1.07 Billion DKK	49.03%
2015 Q2	736 Million DKK	23.91%
2015 Q1	594 Million DKK	-17.5%
2015 Q4	1.07 Billion DKK	70.32%
2015 Q3	630 Million DKK	-14.4%
2014 Q2	406 Million DKK	-49.5%
2014 FY	720 Million DKK	234.88%
2014 Q4	720 Million DKK	153.52%
2014 Q3	284 Million DKK	-30.05%
2014 Q1	804 Million DKK	273.95%
2013 FY	215 Million DKK	-57.0%
2013 Q1	300 Million DKK	-40.0%
2013 Q4	215 Million DKK	-67.91%
2013 Q3	670 Million DKK	-6.42%
2013 Q2	716 Million DKK	138.67%
2012 Q3	1.09 Billion DKK	22.58%
2012 Q4	500 Million DKK	-54.17%
2012 Q2	890 Million DKK	-0.45%
2012 FY	500 Million DKK	-41.38%
2012 Q1	894 Million DKK	4.81%
2011 Q4	853 Million DKK	-61.12%
2011 FY	853 Million DKK	-61.65%
2011 Q1	1.51 Billion DKK	-32.01%
2011 Q2	1.38 Billion DKK	-8.13%
2011 Q3	2.19 Billion DKK	57.96%
2010 Q1	2 Billion DKK	44.38%
2010 Q2	4.28 Billion DKK	113.87%
2010 FY	2.22 Billion DKK	60.23%
2010 Q3	1.99 Billion DKK	-53.43%
2010 Q4	2.22 Billion DKK	11.42%
2009 FY	1.38 Billion DKK	-40.21%
2009 Q3	1.19 Billion DKK	-16.76%
2009 Q1	2.46 Billion DKK	6.01%
2009 Q2	1.43 Billion DKK	-41.81%
2009 Q4	1.38 Billion DKK	16.44%
2008 Q3	1.77 Billion DKK	27.69%
2008 Q4	2.32 Billion DKK	30.48%
2008 Q2	1.39 Billion DKK	-10.03%
2008 Q1	1.54 Billion DKK	13.42%
2008 FY	2.32 Billion DKK	70.02%
2007 Q2	1.25 Billion DKK	-7.87%
2007 Q4	1.36 Billion DKK	6.27%
2007 FY	1.36 Billion DKK	-9.83%
2007 Q1	1.36 Billion DKK	-9.71%
2007 Q3	1.28 Billion DKK	2.0%
2006 Q4	1.51 Billion DKK	2.17%
2006 Q3	1.48 Billion DKK	-1.58%
2006 FY	1.51 Billion DKK	-43.74%
2006 Q2	1.5 Billion DKK	-37.11%
2006 Q1	2.39 Billion DKK	-11.04%
2005 Q2	1.86 Billion DKK	11.5%
2005 Q3	2.12 Billion DKK	14.1%
2005 Q4	2.69 Billion DKK	26.51%
2005 FY	2.69 Billion DKK	57.72%
2005 Q1	1.67 Billion DKK	-2.01%
2004 Q1	1.55 Billion DKK	-10.02%
2004 Q2	1.21 Billion DKK	-22.21%
2004 Q3	1.18 Billion DKK	-2.28%
2004 Q4	1.7 Billion DKK	44.04%
2004 FY	1.7 Billion DKK	-1.48%
2003 FY	1.73 Billion DKK	24.88%
2003 Q4	1.73 Billion DKK	0.0%
2002 Q4	1.38 Billion DKK	0.0%
2002 FY	1.38 Billion DKK	-17.79%
2001 FY	1.68 Billion DKK	-4.37%
2001 Q4	1.68 Billion DKK	0.0%
2000 FY	1.76 Billion DKK	-63.83%
2000 Q4	1.76 Billion DKK	0.0%
1999 FY	4.87 Billion DKK	76.93%
1999 Q4	4.87 Billion DKK	0.0%
1998 FY	2.75 Billion DKK	-11.13%
1998 Q4	2.75 Billion DKK	0.0%
1997 Q4	3.1 Billion DKK	0.0%
1997 FY	3.1 Billion DKK	191.67%
1996 FY	1.06 Billion DKK	-48.02%
1996 Q4	1.06 Billion DKK	0.0%
1995 FY	2.04 Billion DKK	-55.14%
1995 Q4	2.04 Billion DKK	0.0%
1994 Q4	4.56 Billion DKK	0.0%
1994 FY	4.56 Billion DKK	6.01%
1993 FY	4.3 Billion DKK	20.11%
1993 Q4	4.3 Billion DKK	0.0%
1992 FY	3.58 Billion DKK	16.69%
1992 Q4	3.58 Billion DKK	0.0%
1991 Q4	3.07 Billion DKK	0.0%
1991 FY	3.07 Billion DKK	7.36%
1990 FY	2.86 Billion DKK	-15.22%
1990 Q4	2.86 Billion DKK	0.0%
1989 Q4	3.37 Billion DKK	0.0%
1989 FY	3.37 Billion DKK	60.55%

Peer Total Debt Comparison of Novo Nordisk A/S

Name	Total Debt	Total Debt Difference
ALK-Abelló A/S	765 Million DKK	-3430.196%
Bavarian Nordic A/S	145.3 Million DKK	-18486.117%
Genmab A/S	770 Million DKK	-3407.273%
Gubra A/S	71.43 Million DKK	-37704.998%
Orphazyme A/S	- DKK	-Infinity%
Pharma Equity Group A/S	30.22 Million DKK	-89261.702%
Zealand Pharma A/S	200.27 Million DKK	-13384.459%

Global Stocks Search

Novo Nordisk A/S (NOVO-B.CO)

Total Debt Summary of Novo Nordisk A/S

Annual Total Debt Chart of Novo Nordisk A/S (2023 - 1989)

Historical Annual Total Debt of Novo Nordisk A/S (2023 - 1989)

Peer Total Debt Comparison of Novo Nordisk A/S